Sanara
SMTI
Sanara (SMTI) news
Recent news
Sanara MedTech Q2 revenue USD 28.1 million
AInvest Wire · Aug 11, 2026Sanara MedTech Inc: H.C. Wainwright cuts to neutral from buy; cuts target price to $35 from $36
H.C. Wainwright has downgraded its rating for Sanara MedTech (NASDAQ:SMTI) from "Buy" to "Neutral" and reduced its price target to $35 from $36, effective July 30, 2026. This adjustment follows the firm’s reassessment of the company’s financial performance and strategic outlook. The analyst firm…
AInvest Wire · Jul 30, 2026Sanara MedTech - pays no fee or penalty for termination of services agreement - SEC filing
AInvest Wire · Jun 4, 2026Sanara MedTech - shifts strategy to focus on soft tissue repair and bone fusion products - SEC filing
AInvest Wire · Jun 4, 2026Sanara MedTech - terminates services agreement with Catalyst effective June 2, 2026 - SEC filing
AInvest Wire · Jun 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.